Literature DB >> 2518693

A serological survey of Ehrlichia canis, Ehrlichia equi, Rickettsia rickettsii, and Borrelia burgdorferi in dogs in Oklahoma.

S J Rodgers1, R J Morton, C A Baldwin.   

Abstract

Serum samples from 259 dogs were tested for antibodies to Ehrlichia canis, Ehrlichia equi, Rickettsia rickettsii, and Borrelia burgdorferi using the indirect fluorescent antibody test. The sera were obtained from submissions to the Oklahoma Animal Disease Diagnostic Laboratory during a 14-month period from June 1986 through July 1987. The rate for positive antibody titers to E. canis was 53%, to E. equi was 33%, to R. rickettsii was 38%, and to B. burgdorferi was 18%. Higher percentages of sera serologically positive to E. canis were found in the spring through the fall months, but there were no seasonal variations for E. equi, R. rickettsii, and B. burgdorferi. There was no consistent pattern of titers to the 4 antigens when age-groups of the dogs were compared. Forty-four different breeds were tested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2518693     DOI: 10.1177/104063878900100212

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  14 in total

1.  Isolation of the equine granulocytic ehrlichiosis agent, Ehrlichia equi, in tick cell culture.

Authors:  U G Munderloh; J E Madigan; J S Dumler; J L Goodman; S F Hayes; J E Barlough; C M Nelson; T J Kurtti
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

2.  Interlaboratory comparison of titers of antibody to Borrelia burgdorferi and evaluation of a commercial assay using canine sera.

Authors:  R T Greene; D A Hirsch; P L Rottman; T M Gerig
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

3.  Comparison of the nucleotide sequences of 16S rRNA, 444 Ep-ank, and groESL heat shock operon genes in naturally occurring Ehrlichia equi and human granulocytic ehrlichiosis agent isolates from Northern California.

Authors:  J S Chae; J E Foley; J S Dumler; J E Madigan
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Geographic, clinical, serologic, and molecular evidence of granulocytic ehrlichiosis, a likely zoonotic disease, in Minnesota and Wisconsin dogs.

Authors:  B Greig; K M Asanovich; P J Armstrong; J S Dumler
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

5.  Invasion and intracellular development of the human granulocytic ehrlichiosis agent in tick cell culture.

Authors:  U G Munderloh; S D Jauron; V Fingerle; L Leitritz; S F Hayes; J M Hautman; C M Nelson; B W Huberty; T J Kurtti; G G Ahlstrand; B Greig; M A Mellencamp; J L Goodman
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

6.  Nested PCR assay for detection of granulocytic ehrlichiae.

Authors:  R F Massung; K Slater; J H Owens; W L Nicholson; T N Mather; V B Solberg; J G Olson
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

7.  Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic Ehrlichia.

Authors:  J S Dumler; K M Asanovich; J S Bakken; P Richter; R Kimsey; J E Madigan
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

8.  Comparison of selected canine vector-borne diseases between urban animal shelter and rural hunting dogs in Korea.

Authors:  Sun Lim; Peter J Irwin; Seungryong Lee; Myunghwan Oh; Kyusung Ahn; Boyoung Myung; Sungshik Shin
Journal:  Parasit Vectors       Date:  2010-04-08       Impact factor: 3.876

Review 9.  Burden of tick-borne infections on American companion animals.

Authors:  Zenda L Berrada; Sam R Telford
Journal:  Top Companion Anim Med       Date:  2009-11

Review 10.  Host surveys, ixodid tick biology and transmission scenarios as related to the tick-borne pathogen, Ehrlichia canis.

Authors:  R W Stich; John J Schaefer; William G Bremer; Glen R Needham; Sathaporn Jittapalapong
Journal:  Vet Parasitol       Date:  2008-09-12       Impact factor: 2.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.